Provided by Tiger Trade Technology Pte. Ltd.

Edesa Biotech

5.14
-0.2200-4.10%
Post-market: 5.240.1000+1.95%19:55 EDT
Volume:207.94K
Turnover:1.10M
Market Cap:45.67M
PE:-4.49
High:5.76
Open:5.35
Low:5.06
Close:5.36
52wk High:9.37
52wk Low:0.7200
Shares:8.89M
Float Shares:3.70M
Volume Ratio:0.84
T/O Rate:5.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1438
EPS(LYR):-1.2658
ROE:-96.38%
ROA:-55.33%
PB:9.81
PE(LYR):-4.06

Loading ...

Edesa Biotech announces annual general and special shareholder meeting

Reuters
·
Apr 04

Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit

TIPRANKS
·
Apr 01

Edesa Biotech CEO to present Phase 3 paridiprubart ARDS data at ATS summit

Reuters
·
Apr 01

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

GlobeNewswire
·
Apr 01

Edesa Biotech advances EB06 Phase 2 vitiligo study; enrollment begins mid-2026

Reuters
·
Mar 26

Edesa Biotech CEO Pardeep Nijhawan Acquires Common Shares

Reuters
·
Mar 07

BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT

Reuters
·
Mar 07

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM

Reuters
·
Mar 06

Edesa Biotech CEO Makes Bold Insider Move With Fresh Share Purchase

TIPRANKS
·
Mar 06

Edesa Biotech CEO Pardeep Nijhawan Reports Common Share Acquisition

Reuters
·
Mar 04

Edesa Biotech CEO Makes Bold Insider Move With Fresh Share Purchase

TIPRANKS
·
Mar 03

Edesa Biotech CEO Pardeep Nijhawan Acquires Common Shares

Reuters
·
Mar 03

AbbVie Inc Stock Closed Up by 3.12% on Feb 27: What Signal Does It Send?

TradingKey
·
Feb 28

Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know

TradingKey
·
Feb 28

BRIEF-Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study

Reuters
·
Feb 24

Edesa Biotech Reports Phase 3 Paridiprubart Trial Cuts 28-Day Mortality

Reuters
·
Feb 24

Edesa Biotech Inc: Safety Profile Was Consistent With Prior Clinical Exposures, With More Than 400 Patients NOW Having Received Paridiprubart

THOMSON REUTERS
·
Feb 24

Edesa Biotech Inc - Paridiprubart Reduces Mortality to 15% in Non-Imv Patients

THOMSON REUTERS
·
Feb 24

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

GlobeNewswire
·
Feb 24

Edesa Biotech reports Q1 EPS (28c), consensus (45c)

TIPRANKS
·
Feb 14